[{"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-001", "question": "A 16-year-old male presents with recurrent stroke-like episodes, mitochondrial myopathy, and lactic acidosis. Muscle biopsy reveals 38% heteroplasmy for the m.3243A>G mutation. Based on current mitochondrial disease criteria, what is the significance of this heteroplasmy level?", "options": ["Insufficient for MELAS diagnosis; >60% required in muscle", "Diagnostic of MELAS; clinical correlation unnecessary", "Above the threshold for clinical expression; supports diagnosis with compatible phenotype", "Only significant if confirmed in blood at >20%", "Requires repeat biopsy; sampling error likely"], "answer": "C", "answer_index": 2, "explanation": "In MELAS, >40% heteroplasmy in muscle correlates with clinical manifestation, but levels of 30-40% with typical phenotype are considered diagnostic. Blood heteroplasmy is less sensitive and declines with age. The threshold concept is critical for interpreting borderline results.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 16-year-old with recurrent stroke-like episodes, mitochondrial myopathy, lactic acidosis—classic MELAS phenotype—plus muscle biopsy showing 38% heteroplasmy for m.3243A>G. The explanation notes that >40% heteroplasmy generally correlates with clinical manifestation, but 30–40% in the setting of a very typical phenotype is considered diagnostic and above the functional threshold.\\nOption C correctly reflects that this heteroplasmy level is above the threshold for clinical expression and, together with a compatible phenotype, supports the diagnosis; it properly emphasizes the need for clinical correlation. Option A is too rigid and conflicts with the stated 30–40% diagnostic window. B incorrectly implies genetics alone are diagnostic without clinical context. D overemphasizes blood heteroplasmy, which is known to be less sensitive and age-dependent. E incorrectly implies that 38% is likely sampling error needing repeat biopsy.\\nMain medical accuracy: Content aligns with current understanding of heteroplasmy thresholds and phenotype correlation in MELAS, with appropriate nuance about tissue differences and threshold concept.\\nMinimal fix: Slightly reword the explanation to cite an evidence-based range (e.g., “~30–40% or higher in muscle with classic MELAS features”) to avoid suggesting rigid cutoffs.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 16-year-old with recurrent stroke-like episodes, mitochondrial myopathy, lactic acidosis—classic MELAS phenotype—plus muscle biopsy showing 38% heteroplasmy for m.3243A>G. The explanation notes that >40% heteroplasmy generally correlates with clinical manifestation, but 30–40% in the setting of a very typical phenotype is considered diagnostic and above the functional threshold.\nOption C correctly reflects that this heteroplasmy level is above the threshold for clinical expression and, together with a compatible phenotype, supports the diagnosis; it properly emphasizes the need for clinical correlation. Option A is too rigid and conflicts with the stated 30–40% diagnostic window. B incorrectly implies genetics alone are diagnostic without clinical context. D overemphasizes blood heteroplasmy, which is known to be less sensitive and age-dependent. E incorrectly implies that 38% is likely sampling error needing repeat biopsy.\nMain medical accuracy: Content aligns with current understanding of heteroplasmy thresholds and phenotype correlation in MELAS, with appropriate nuance about tissue differences and threshold concept.\nMinimal fix: Slightly reword the explanation to cite an evidence-based range (e.g., “~30–40% or higher in muscle with classic MELAS features”) to avoid suggesting rigid cutoffs.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-002", "question": "A 19-year-old asymptomatic athlete has a QTc of 315ms on pre-participation screening. Family history reveals sudden cardiac death in a paternal uncle. Genetic testing identifies a gain-of-function KCNH2 mutation (c.1764G>C). According to 2022 ESC guidelines for SQTS, what is the recommended management?", "options": ["No therapy; restriction from competitive sports", "Implantable cardioverter-defibrillator regardless of symptoms", "Quinidine 600mg daily to maintain QTc >360ms", "Flecainide 100mg twice daily for rhythm stabilization", "Annual Holter monitoring without pharmacotherapy"], "answer": "C", "answer_index": 2, "explanation": "For asymptomatic SQTS patients with pathogenic KCNH2 mutations, quinidine is recommended to prolong QT interval and reduce arrhythmia risk. ICD is reserved for symptomatic patients or those with aborted SCD. Flecainide is contraindicated in SQTS.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: M (multiple defensible answers, with U elements re: exact dose/threshold)\\nVerdict on keyed answer: Not uniquely determinable as written\\n\\nKey stem clues: 19-year-old asymptomatic athlete, QTc 315 ms (very short), documented gain-of-function KCNH2 mutation, family history of sudden cardiac death, explicit reference to 2022 ESC SQTS guidelines, options including ICD, quinidine, sports restriction, and observation. The key aims to test that quinidine is first-line to prolong QT and prevent arrhythmias in genetically confirmed SQTS even if asymptomatic, and that ICD is not mandatory in all such patients.\\n\\nLogical issues: Option C specifies a fixed dose (600 mg daily) and a target QTc >360 ms. ESC guidance recommends quinidine to prolong QT and prevent arrhythmias but does not mandate this exact dose or QTc threshold; therapy is individualized. Thus the question over-specifies details that are not guideline-based, while E (annual monitoring without therapy) is also a plausible, conservative interpretation for an asymptomatic patient, creating ambiguity. Also, A (no therapy; sports restriction) is not aligned with guidelines but reflects another plausible management concept.\\n\\nMedical accuracy: Core teaching (quinidine preferred; ICD not for all, flecainide contraindicated) is correct; dose/target QTc are questionable specifics.\\n\\nMinimal fix: Rephrase option C generically as “Initiate quinidine therapy to prolong QT interval and reduce arrhythmic risk” without a specific dose/target QTc, and clarify in stem that guidelines recommend pharmacologic QT-prolongation even in asymptomatic mutation carriers.\\n\",\"medical_accuracy_score\":\"4\",\"logical_validity\":false,\"logical_false_reason\":\"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (multiple defensible answers, with U elements re: exact dose/threshold)\nVerdict on keyed answer: Not uniquely determinable as written\n\nKey stem clues: 19-year-old asymptomatic athlete, QTc 315 ms (very short), documented gain-of-function KCNH2 mutation, family history of sudden cardiac death, explicit reference to 2022 ESC SQTS guidelines, options including ICD, quinidine, sports restriction, and observation. The key aims to test that quinidine is first-line to prolong QT and prevent arrhythmias in genetically confirmed SQTS even if asymptomatic, and that ICD is not mandatory in all such patients.\n\nLogical issues: Option C specifies a fixed dose (600 mg daily) and a target QTc >360 ms. ESC guidance recommends quinidine to prolong QT and prevent arrhythmias but does not mandate this exact dose or QTc threshold; therapy is individualized. Thus the question over-specifies details that are not guideline-based, while E (annual monitoring without therapy) is also a plausible, conservative interpretation for an asymptomatic patient, creating ambiguity. Also, A (no therapy; sports restriction) is not aligned with guidelines but reflects another plausible management concept.\n\nMedical accuracy: Core teaching (quinidine preferred; ICD not for all, flecainide contraindicated) is correct; dose/target QTc are questionable specifics.\n\nMinimal fix: Rephrase option C generically as “Initiate quinidine therapy to prolong QT interval and reduce arrhythmic risk” without a specific dose/target QTc, and clarify in stem that guidelines recommend pharmacologic QT-prolongation even in asymptomatic mutation carriers.\n", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-003", "question": "A 62-year-old woman with Graves disease presents in thyroid storm (Burch-Wartofsky score 65) with pulmonary edema and cardiogenic shock (LVEF 15%, CI 1.8 L/min/m²). She cannot tolerate beta-blockers due to severe decompensation. Which vasoactive agent is most appropriate initial therapy?", "options": ["Norepinephrine for vasopressor support", "Dobutamine for inotropic effect", "Milrinone 0.5 mcg/kg/min for inodilation", "Levosimendan 0.1 mcg/kg/min calcium sensitizer", "Dopamine 10 mcg/kg/min for combined effect"], "answer": "C", "answer_index": 2, "explanation": "In thyroid storm with cardiogenic shock, beta-blockers are contraindicated. Milrinone provides inotropy via phosphodiesterase inhibition independent of beta-adrenergic receptors and offers vasodilation to reduce afterload. Levosimendan is less preferred due to limited data and potential arrhythmogenicity.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: M (multiple defensible answers, borderline miskey)\\nVerdict on keyed answer: Not uniquely determinable; C is reasonable but not clearly superior to A or B\\nKey stem clues: Thyroid storm, severe cardiogenic shock (LVEF 15%, CI 1.8), pulmonary edema; patient cannot tolerate beta-blockers. Question: “Which vasoactive agent is most appropriate initial therapy?”\\nMilrinone (C) is a PDE-3 inhibitor giving inotropy and vasodilation independent of beta-receptors and is appropriate inotrope for low-output state without using beta-blockade. However, in cardiogenic shock the usual initial priority is maintaining MAP/perfusion, for which norepinephrine (A) is guideline-preferred first-line vasopressor. Many patients in this hemodynamic profile would require NE as initial drug, then add an inotrope. Dobutamine (B) is also a standard first-line inotrope in cardiogenic shock; beta stimulation is not contraindicated, only beta-blockade is problematic.\\nThus more than one option (A, B, C) can be defended as “most appropriate initial therapy,” and the stem does not specify blood pressure/MAP or SVR to justify choosing inodilator over vasopressor or beta-agonist inotrope.\\nMain medical accuracy: rationale about milrinone’s beta-independence is correct but oversimplifies real-world initial management.\\nMinimal fix: Specify hypotension/SVR pattern and explicitly ask for “best inotrope that avoids beta-adrenergic receptor stimulation,” or change key to norepinephrine and rewrite rationale accordingly.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":false,\"logical_false_reason\":\"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (multiple defensible answers, borderline miskey)\nVerdict on keyed answer: Not uniquely determinable; C is reasonable but not clearly superior to A or B\nKey stem clues: Thyroid storm, severe cardiogenic shock (LVEF 15%, CI 1.8), pulmonary edema; patient cannot tolerate beta-blockers. Question: “Which vasoactive agent is most appropriate initial therapy?”\nMilrinone (C) is a PDE-3 inhibitor giving inotropy and vasodilation independent of beta-receptors and is appropriate inotrope for low-output state without using beta-blockade. However, in cardiogenic shock the usual initial priority is maintaining MAP/perfusion, for which norepinephrine (A) is guideline-preferred first-line vasopressor. Many patients in this hemodynamic profile would require NE as initial drug, then add an inotrope. Dobutamine (B) is also a standard first-line inotrope in cardiogenic shock; beta stimulation is not contraindicated, only beta-blockade is problematic.\nThus more than one option (A, B, C) can be defended as “most appropriate initial therapy,” and the stem does not specify blood pressure/MAP or SVR to justify choosing inodilator over vasopressor or beta-agonist inotrope.\nMain medical accuracy: rationale about milrinone’s beta-independence is correct but oversimplifies real-world initial management.\nMinimal fix: Specify hypotension/SVR pattern and explicitly ask for “best inotrope that avoids beta-adrenergic receptor stimulation,” or change key to norepinephrine and rewrite rationale accordingly.", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-004", "question": "A 6-year-old boy presents with recurrent lacunar strokes, livedo racemosa, and systemic vasculitis. ADA2 enzyme activity is <5% of normal. Genetic testing confirms biallelic loss-of-function ADA2 mutations. What is the first-line therapy for preventing further cerebrovascular events?", "options": ["High-dose prednisone with cyclophosphamide induction", "Rituximab 750mg/m² every 4 weeks", "Etanercept 0.8mg/kg weekly subcutaneously", "Anakinra 2mg/kg daily subcutaneously", "Aspirin 5mg/kg daily antiplatelet therapy"], "answer": "C", "answer_index": 2, "explanation": "DADA2 is a monogenic interferonopathy where TNF-α drives vasculitic manifestations. TNF inhibition with etanercept prevents stroke recurrence and treats systemic vasculitis, while traditional immunosuppressants are ineffective. IL-1 blockade is second-line.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 6‑year‑old with recurrent lacunar strokes, livedo racemosa, systemic vasculitis, ADA2 activity <5% and biallelic loss‑of‑function ADA2 mutations → classic deficiency of adenosine deaminase 2 (DADA2). Current evidence and consensus in pediatric rheumatology/hematology support TNF‑α inhibitors as first‑line, stroke‑preventive therapy in DADA2, with etanercept among the most commonly used agents.\\nOption C (etanercept) directly targets TNF‑α, fitting the stem’s note that TNF drives vasculitic manifestations and that TNF inhibition prevents stroke recurrence. Options A and B (high‑dose steroids/cyclophosphamide; rituximab) are reported as relatively ineffective or clearly inferior for preventing cerebrovascular events in DADA2. Option D (anakinra, IL‑1 blockade) may be considered second‑line or for refractory/intolerant cases, not first‑line. Option E (aspirin) alone is inadequate to prevent strokes in this monogenic vasculitis and is adjunctive at best.\\nMain logical issues: None; the stem clearly specifies the diagnosis and asks for first‑line prevention, which uniquely supports TNF inhibition.\\nMain medical accuracy issues: None significant; characterization of TNF‑α’s role and TNF inhibitor efficacy is consistent with current literature.\\nMinimal fix: Add a brief line such as “Current guidelines recommend TNF‑α inhibitors as first‑line therapy” to reinforce the intended teaching point, though not strictly necessary.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 6‑year‑old with recurrent lacunar strokes, livedo racemosa, systemic vasculitis, ADA2 activity <5% and biallelic loss‑of‑function ADA2 mutations → classic deficiency of adenosine deaminase 2 (DADA2). Current evidence and consensus in pediatric rheumatology/hematology support TNF‑α inhibitors as first‑line, stroke‑preventive therapy in DADA2, with etanercept among the most commonly used agents.\nOption C (etanercept) directly targets TNF‑α, fitting the stem’s note that TNF drives vasculitic manifestations and that TNF inhibition prevents stroke recurrence. Options A and B (high‑dose steroids/cyclophosphamide; rituximab) are reported as relatively ineffective or clearly inferior for preventing cerebrovascular events in DADA2. Option D (anakinra, IL‑1 blockade) may be considered second‑line or for refractory/intolerant cases, not first‑line. Option E (aspirin) alone is inadequate to prevent strokes in this monogenic vasculitis and is adjunctive at best.\nMain logical issues: None; the stem clearly specifies the diagnosis and asks for first‑line prevention, which uniquely supports TNF inhibition.\nMain medical accuracy issues: None significant; characterization of TNF‑α’s role and TNF inhibitor efficacy is consistent with current literature.\nMinimal fix: Add a brief line such as “Current guidelines recommend TNF‑α inhibitors as first‑line therapy” to reinforce the intended teaching point, though not strictly necessary.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-005", "question": "A 30-year-old G2P1 at 32 weeks gestation presents with fetal hydrops and mirror syndrome. Which pathophysiologic mechanism best explains her severe preeclampsia-like features?", "options": ["Massive fetomaternal hemorrhage causing maternal anemia", "Placental edema releasing soluble fms-like tyrosine kinase-1 (sFlt-1)", "Maternal antibody production against fetal Rh antigens", "Amniotic fluid embolism triggering systemic inflammation", "Mirror syndrome is a misdiagnosis; this is atypical HELLP"], "answer": "B", "answer_index": 1, "explanation": "Mirror syndrome involves placental edema that mechanically compromises uteroplacental perfusion and releases anti-angiogenic factors like sFlt-1, creating a preeclampsia phenotype. Resolution occurs within 48 hours of delivery or fetal therapy that reduces hydrops.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 30-year-old pregnant woman at 32 weeks with fetal hydrops and maternal mirror syndrome, described as having severe preeclampsia-like features. Mirror syndrome is classically associated with placental edema in the setting of fetal hydrops, leading to a maternal syndrome that mimics preeclampsia via anti-angiogenic factor release (notably sFlt-1) from the edematous placenta.\\nOption B correctly identifies placental edema releasing sFlt-1 as the mechanism for the maternal preeclampsia-like phenotype. A (fetomaternal hemorrhage) can cause maternal anemia and fetal anemia/hydrops but does not directly explain maternal preeclampsia features. C (Rh antibodies) explains a cause of hydrops, not the maternal syndrome. D (amniotic fluid embolism) presents acutely with respiratory distress and DIC, not a chronic mirror syndrome picture. E incorrectly dismisses mirror syndrome and mislabels it as atypical HELLP.\\nThere is no internal contradiction and one clearly superior answer that matches current understanding of mirror syndrome pathophysiology.\\nMain medical accuracy issue: minor—explanation’s reference to ‘mechanically compromises uteroplacental perfusion’ is somewhat speculative; the central anti-angiogenic mechanism is accurate. \\nMinimal fix: Clarify in the explanation that the dominant mechanism is excess anti-angiogenic factor release from the edematous placenta rather than purely mechanical compromise.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 30-year-old pregnant woman at 32 weeks with fetal hydrops and maternal mirror syndrome, described as having severe preeclampsia-like features. Mirror syndrome is classically associated with placental edema in the setting of fetal hydrops, leading to a maternal syndrome that mimics preeclampsia via anti-angiogenic factor release (notably sFlt-1) from the edematous placenta.\nOption B correctly identifies placental edema releasing sFlt-1 as the mechanism for the maternal preeclampsia-like phenotype. A (fetomaternal hemorrhage) can cause maternal anemia and fetal anemia/hydrops but does not directly explain maternal preeclampsia features. C (Rh antibodies) explains a cause of hydrops, not the maternal syndrome. D (amniotic fluid embolism) presents acutely with respiratory distress and DIC, not a chronic mirror syndrome picture. E incorrectly dismisses mirror syndrome and mislabels it as atypical HELLP.\nThere is no internal contradiction and one clearly superior answer that matches current understanding of mirror syndrome pathophysiology.\nMain medical accuracy issue: minor—explanation’s reference to ‘mechanically compromises uteroplacental perfusion’ is somewhat speculative; the central anti-angiogenic mechanism is accurate. \nMinimal fix: Clarify in the explanation that the dominant mechanism is excess anti-angiogenic factor release from the edematous placenta rather than purely mechanical compromise.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-006", "question": "A 50-year-old with eosinophilic granulomatosis with polyangiitis undergoes cardiac MRI for suspected myocarditis. Late gadolinium enhancement shows predominant subendocardial involvement with sparing of the epicardium. What is the prognostic implication?", "options": ["Indicates active eosinophilic myocarditis responsive to steroids", "Suggests concomitant coronary artery disease requiring angiography", "Represents fibrotic replacement predicting poor response to immunosuppression", "Typical pattern with no impact on treatment decisions", "Requires endomyocardial biopsy for definitive diagnosis"], "answer": "C", "answer_index": 2, "explanation": "In EGPA, subendocardial LGE pattern indicates chronic fibrotic replacement rather than active inflammation, predicting poor response to immunosuppressive therapy and worse cardiac outcomes. Epicardial LGE correlates with active myocarditis and treatment responsiveness.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Patient with known eosinophilic granulomatosis with polyangiitis (EGPA); cardiac MRI done for suspected myocarditis; late gadolinium enhancement shows predominant subendocardial involvement with sparing of the epicardium; question asks for prognostic implication.\\nIn EGPA and other eosinophilic myocarditides, subendocardial LGE is classically associated with chronic damage and fibrotic replacement (endomyocardial disease), whereas epicardial or mid‑myocardial LGE aligns more with active inflammation responsive to immunosuppression. Therefore, option C—“Represents fibrotic replacement predicting poor response to immunosuppression”—accurately reflects the prognostic implication and matches the explanation.\\nOption A reverses this association (incorrect: active myocarditis more often non‑subendocardial). B is not supported; subendocardial LGE from EGPA does not by itself mandate ischemic workup. D is wrong because this finding has clear therapeutic/prognostic impact. E is too strong; diagnosis and prognostic inference can often be made noninvasively and biopsy is not routinely required.\\nNo major medical inaccuracies are evident; content aligns with current understanding of CMR patterns in EGPA/eosinophilic myocarditis.\\nMinimal fix: Clarify in stem that ischemic heart disease has been excluded to further reduce any possible confusion with infarct‑type subendocardial LGE.\\n\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Patient with known eosinophilic granulomatosis with polyangiitis (EGPA); cardiac MRI done for suspected myocarditis; late gadolinium enhancement shows predominant subendocardial involvement with sparing of the epicardium; question asks for prognostic implication.\nIn EGPA and other eosinophilic myocarditides, subendocardial LGE is classically associated with chronic damage and fibrotic replacement (endomyocardial disease), whereas epicardial or mid‑myocardial LGE aligns more with active inflammation responsive to immunosuppression. Therefore, option C—“Represents fibrotic replacement predicting poor response to immunosuppression”—accurately reflects the prognostic implication and matches the explanation.\nOption A reverses this association (incorrect: active myocarditis more often non‑subendocardial). B is not supported; subendocardial LGE from EGPA does not by itself mandate ischemic workup. D is wrong because this finding has clear therapeutic/prognostic impact. E is too strong; diagnosis and prognostic inference can often be made noninvasively and biopsy is not routinely required.\nNo major medical inaccuracies are evident; content aligns with current understanding of CMR patterns in EGPA/eosinophilic myocarditis.\nMinimal fix: Clarify in stem that ischemic heart disease has been excluded to further reduce any possible confusion with infarct‑type subendocardial LGE.\n", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-007", "question": "An 11-month-old infant presents with a large CNS tumor. Histopathology shows rhabdoid cells with loss of SMARCB1 immunostaining. Molecular profiling reveals a TYR-methylation class. What is the most critical prognostic factor in this subtype?", "options": ["Presence of SMARCB1 deletion alone", "Age <3 years at diagnosis", "MYC oncogene amplification status", "DNA methylation subclassification", "Extent of surgical resection"], "answer": "D", "answer_index": 3, "explanation": "In ATRT, the methylation class (TYR, SHH, MYC) is the dominant prognostic factor, with TYR class having 90% 5-year survival compared to <30% for MYC. SMARCB1 loss is universal, and age is secondary to molecular subclassification in risk stratification.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 11‑month-old with large CNS tumor; rhabdoid histology; loss of SMARCB1 (INI1) staining; molecular profiling reveals TYR methylation class; question asks for the most critical prognostic factor in this subtype. These clearly indicate atypical teratoid/rhabdoid tumor (ATRT) and specifically the ATRT-TYR methylation subgroup. Current data show that DNA methylation subclass (TYR vs SHH vs MYC) is the dominant stratifier for prognosis, with TYR associated with markedly better survival than MYC, and more impactful than age or extent of resection in modern risk models. Thus option D is the uniquely best answer.\\nOther options: A) SMARCB1 deletion is near-universal and not discriminatory prognostically. B) Young age is adverse but secondary to methylation class. C) MYC amplification relates to the MYC subgroup, but in the question’s TYR context it’s not the primary prognostic factor. E) Extent of resection influences outcome but is less defining than molecular class in ATRT.\\nMain medical issues: None significant; teaching point is accurate and contemporary.\\nMinimal fix: Explicitly name ATRT in the stem to ensure all examinees recognize the tumor entity targeted by the question.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 11‑month-old with large CNS tumor; rhabdoid histology; loss of SMARCB1 (INI1) staining; molecular profiling reveals TYR methylation class; question asks for the most critical prognostic factor in this subtype. These clearly indicate atypical teratoid/rhabdoid tumor (ATRT) and specifically the ATRT-TYR methylation subgroup. Current data show that DNA methylation subclass (TYR vs SHH vs MYC) is the dominant stratifier for prognosis, with TYR associated with markedly better survival than MYC, and more impactful than age or extent of resection in modern risk models. Thus option D is the uniquely best answer.\nOther options: A) SMARCB1 deletion is near-universal and not discriminatory prognostically. B) Young age is adverse but secondary to methylation class. C) MYC amplification relates to the MYC subgroup, but in the question’s TYR context it’s not the primary prognostic factor. E) Extent of resection influences outcome but is less defining than molecular class in ATRT.\nMain medical issues: None significant; teaching point is accurate and contemporary.\nMinimal fix: Explicitly name ATRT in the stem to ensure all examinees recognize the tumor entity targeted by the question.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-008", "question": "A 76-year-old man with wild-type transthyretin amyloidosis (ATTRwt) has LV wall thickness 16mm and LVEF 45%. Which speckle-tracking echocardiographic finding best distinguishes this from hypertensive heart disease?", "options": ["Global longitudinal strain -8%", "Relative apical sparing ratio >1.5", "Basal sparing pattern", "Circumferential strain >-15%", "Longitudinal strain <10% with basal predominance"], "answer": "B", "answer_index": 1, "explanation": "Relative apical sparing ratio (average apical strain / average basal strain) >1.5 is 93% specific for cardiac amyloidosis, reflecting base-to-apex gradient of amyloid deposition. This pattern is not seen in hypertensive heart disease where strain reduction is homogeneous.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Older man with wild-type transthyretin amyloidosis, increased LV wall thickness, mildly reduced LVEF; question specifically asks for the speckle‑tracking echo finding that best distinguishes this from hypertensive heart disease. In current literature, relative apical sparing of longitudinal strain (apical/basal ratio >1.5) is a characteristic and relatively specific pattern for cardiac amyloidosis and not typical of hypertensive LVH, which shows more homogeneous strain reduction.\\nOption B correctly describes the relative apical sparing ratio >1.5. Options A and E (severely reduced global longitudinal strain, basal‑predominant reduction) are not specific and can be seen in other cardiomyopathies, including hypertensive disease. Option C (“basal sparing”) is the opposite of the classic amyloid pattern. Option D (circumferential strain >−15%) is nonspecific and not the classic discriminator between amyloid and hypertensive heart disease.\\nNo internal contradictions or underspecification: the item is focused on a well‑defined, widely accepted echo marker.\\nMain medical accuracy issue: none; explanation and cutoff (~1.5, high specificity) are consistent with contemporary data.\\nMinimal fix: Clarify in stem that the comparison is to “hypertensive left ventricular hypertrophy without amyloidosis” to avoid any ambiguity.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Older man with wild-type transthyretin amyloidosis, increased LV wall thickness, mildly reduced LVEF; question specifically asks for the speckle‑tracking echo finding that best distinguishes this from hypertensive heart disease. In current literature, relative apical sparing of longitudinal strain (apical/basal ratio >1.5) is a characteristic and relatively specific pattern for cardiac amyloidosis and not typical of hypertensive LVH, which shows more homogeneous strain reduction.\nOption B correctly describes the relative apical sparing ratio >1.5. Options A and E (severely reduced global longitudinal strain, basal‑predominant reduction) are not specific and can be seen in other cardiomyopathies, including hypertensive disease. Option C (“basal sparing”) is the opposite of the classic amyloid pattern. Option D (circumferential strain >−15%) is nonspecific and not the classic discriminator between amyloid and hypertensive heart disease.\nNo internal contradictions or underspecification: the item is focused on a well‑defined, widely accepted echo marker.\nMain medical accuracy issue: none; explanation and cutoff (~1.5, high specificity) are consistent with contemporary data.\nMinimal fix: Clarify in stem that the comparison is to “hypertensive left ventricular hypertrophy without amyloidosis” to avoid any ambiguity.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-009", "question": "A 45-year-old woman with severe verapamil overdose (ingestion 4 hours ago) presents with hypotension (SBP 70mmHg) and hyperglycemia (420mg/dL). You initiate high-dose insulin euglycemia therapy (HIET). What is the target serum glucose range during the first 24 hours?", "options": ["80-110 mg/dL (tight glycemic control)", "110-180 mg/dL (moderate control)", "180-250 mg/dL (permissive hyperglycemia)", "250-350 mg/dL (severe hyperglycemia acceptable)", "No specific target; follow institutional protocol"], "answer": "B", "answer_index": 1, "explanation": "HIET requires maintaining glucose 110-180 mg/dL to prevent hypoglycemia during high-dose insulin infusion (0.5-1 unit/kg/hr) while allowing insulin's inotropic effects. Tighter targets risk hypoglycemia; higher targets may impair insulin's metabolic benefits.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Severe verapamil overdose, high-dose insulin euglycemia therapy (HIET) already initiated, question explicitly asks for “target serum glucose range during the first 24 hours.” This clearly frames an ICU/HIET management question, where preventing hypoglycemia during very high insulin dosing is key, but extreme hyperglycemia is also undesirable. Current toxicology and critical care references recommend maintaining serum glucose roughly in the standard ICU range (about 110–180 mg/dL) during HIET, with frequent monitoring and dextrose titration.\\nOption B (110–180 mg/dL) matches this commonly cited target and the rationale given. Option A (80–110) is unnecessarily tight and increases hypoglycemia risk under high-dose insulin. Options C and D allow excessive hyperglycemia and are not recommended for HIET. Option E is too vague for a board-style question that clearly asks for a numeric target.\\nMain medical accuracy issues: None significant; wording about “insulin’s metabolic benefits” is acceptable though somewhat simplified.\\nMinimal fix: Specify “according to current toxicology recommendations, serum glucose is typically maintained between 110–180 mg/dL with frequent checks” in the explanation to reinforce evidence basis, but no change to stem/choices/key is required for validity.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Severe verapamil overdose, high-dose insulin euglycemia therapy (HIET) already initiated, question explicitly asks for “target serum glucose range during the first 24 hours.” This clearly frames an ICU/HIET management question, where preventing hypoglycemia during very high insulin dosing is key, but extreme hyperglycemia is also undesirable. Current toxicology and critical care references recommend maintaining serum glucose roughly in the standard ICU range (about 110–180 mg/dL) during HIET, with frequent monitoring and dextrose titration.\nOption B (110–180 mg/dL) matches this commonly cited target and the rationale given. Option A (80–110) is unnecessarily tight and increases hypoglycemia risk under high-dose insulin. Options C and D allow excessive hyperglycemia and are not recommended for HIET. Option E is too vague for a board-style question that clearly asks for a numeric target.\nMain medical accuracy issues: None significant; wording about “insulin’s metabolic benefits” is acceptable though somewhat simplified.\nMinimal fix: Specify “according to current toxicology recommendations, serum glucose is typically maintained between 110–180 mg/dL with frequent checks” in the explanation to reinforce evidence basis, but no change to stem/choices/key is required for validity.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-010", "question": "A 35-year-old man develops DRESS syndrome 3 weeks after starting phenytoin. He has fever, eosinophilia, atypical lymphocytosis, and transaminitis (AST 450 U/L). HHV-6 PCR becomes positive at day 16 of illness. What is the clinical significance of this virologic finding?", "options": ["Confirms phenytoin as the causative drug", "Indicates need for ganciclovir antiviral therapy", "Predicts higher risk of disease flare and organ damage", "Represents asymptomatic viral reactivation without prognostic value", "Suggests alternative diagnosis of acute HHV-6 infection"], "answer": "C", "answer_index": 2, "explanation": "HHV-6 reactivation at weeks 2-3 in DRESS is pathogenically linked to disease severity, predicting higher risk of relapse, end-organ damage, and prolonged course. It indicates need for more aggressive immunosuppression, not antiviral therapy, as the virus is a marker of immune dysregulation.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Adult with classic DRESS features (fever, eosinophilia, atypical lymphocytes, liver involvement) 3 weeks after starting phenytoin; HHV-6 PCR becomes positive at day 16. In DRESS, delayed HHV-6 reactivation (around weeks 2–3) is well described as part of the pathogenic cascade and correlates with more severe/prolonged disease, higher relapse risk, and organ involvement. Thus option C, stating it predicts higher risk of disease flare and organ damage, is accurate and best.\\nOther options: A is incorrect because HHV-6 reactivation does not specifically confirm phenytoin as the culprit; many drugs can cause DRESS. B is incorrect: antiviral therapy (e.g., ganciclovir) is not standard; immunosuppression is. D is inaccurate because the reactivation does have prognostic value. E is incorrect: timing within established DRESS and typical context favor reactivation, not primary acute HHV-6 infection.\\nMain medical accuracy issues: None significant; teaching point matches current understanding.\\nMinimal fix: Option B could specify “is recommended as standard of care” to highlight its incorrectness and avoid any ambiguity about investigational antiviral use in research settings.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Adult with classic DRESS features (fever, eosinophilia, atypical lymphocytes, liver involvement) 3 weeks after starting phenytoin; HHV-6 PCR becomes positive at day 16. In DRESS, delayed HHV-6 reactivation (around weeks 2–3) is well described as part of the pathogenic cascade and correlates with more severe/prolonged disease, higher relapse risk, and organ involvement. Thus option C, stating it predicts higher risk of disease flare and organ damage, is accurate and best.\nOther options: A is incorrect because HHV-6 reactivation does not specifically confirm phenytoin as the culprit; many drugs can cause DRESS. B is incorrect: antiviral therapy (e.g., ganciclovir) is not standard; immunosuppression is. D is inaccurate because the reactivation does have prognostic value. E is incorrect: timing within established DRESS and typical context favor reactivation, not primary acute HHV-6 infection.\nMain medical accuracy issues: None significant; teaching point matches current understanding.\nMinimal fix: Option B could specify “is recommended as standard of care” to highlight its incorrectness and avoid any ambiguity about investigational antiviral use in research settings.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]